Research output per year
Research output per year
Fingerprint
Dive into the research topics where Julia Katharina Schwarze is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Research output
-
A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors
Awada, G., Schwarze, J. K., Tijtgat, J., Fasolino, G., Kruse, V. & Neyns, B., 1 Jun 2022, In : Melanoma Research. 32, 3, p. 183-191 9 p.Research output: Contribution to journal › Article
-
Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial
Schwarze, J. K., Garaud, S., Jansen, Y., Awada, G., Vandersleyen, V., Tijtgat, J., de Wind, A., Kristanto, P., Seremet, T., Willard-Gallo, K. & Neyns, B., Feb 2022, In : Cancers (Basel). 14, 3, 22 p., 682.Research output: Contribution to journal › Article
Open Access -
Oncolytic Herpes Simplex Virus Type 1 Induces Immunogenic Cell Death Resulting in Maturation of BDCA-1+ Myeloid Dendritic Cells
Kalus, P., De Munck, J., Vanbellingen, S., Carreer, L., Laeremans, T., Broos, K., Dufait, I., Schwarze, J. K., Van Riet, I., Neyns, B., Breckpot, K. & Aerts, J., May 2022, In : International Journal of Molecular Sciences. 23, 9, 17 p., 4865.Research output: Contribution to journal › Article
-
371P - Low-dose bevacizumab for the treatment of focal post-radiation necrosis of the brain
Tijtgat, J., Schwarze, J. K. & Awada, G., 16 Sep 2021.Research output: Unpublished contribution to conference › Poster
-
Abstract 962MO. A phase I clinical trial on intratumoral injection of autologous CD1C (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells (myDC) in combination with talimogene laherparepvec (T-VEC) in patients with advanced pretreated melanoma
Schwarze, J. K., Tijtgat, J., Awada, G., Cras, L., Dufait, I., Forsyth, R., Van Riet, I., Tuyaerts, S. & Neyns, B., 1 Sep 2021, In : Annals of Oncology. 32, p. S832-S833Research output: Contribution to journal › Meeting abstract (Journal)
Prizes
-
Best Poster Award
Gil Awada (Recipient), Ibrahim Özdemir (Recipient), Julia Katharina Schwarze (Recipient), Emma Daeninck (Recipient), Odrade Gondry (Recipient), Yanina Jansen (Recipient), Teofila Seremet (Recipient), Marleen Keyaerts (Recipient), Hendrik Everaert (Recipient) & Bart Neyns (Recipient), 15 Dec 2018
Prize: Prize (including medals and awards)
-
Oral presentation 3rd prize
Julia Katharina Schwarze (Recipient), 7 Feb 2020
Prize: Prize (including medals and awards)
-
962MO A phase I clinical trial on intratumoral injection of autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells (myDC) in combination with talimogene laherparepvec (T-VEC) in patients with advanced pretreated melanoma
Julia Katharina Schwarze (Speaker)17 Sep 2021Activity: Talk or presentation › Talk or presentation at a conference
-
A phase I clinical trial on intratumoral injection of autologous CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec (T-VEC) in patients with advanced pretreated melanoma
Julia Katharina Schwarze (Presenter), Jens Tijtgat (Contributor), Gil Awada (Contributor), Louise Cras (Contributor), Inès Dufait (Contributor), Ramses Forsyth (Contributor), Sandra Tuyaerts (Contributor), Bart Neyns (Contributor)17 Sep 2021Activity: Talk or presentation › Talk or presentation at a conference
-
A phase I clinical trial on intratumoral administration of autologous CD1c(BDCA-1)+ myeloid dendritic cells plus talimogene laherparepvec (T-VEC) in patients with advanced melanoma
Julia Katharina Schwarze (Speaker)7 Feb 2020Activity: Talk or presentation › Talk or presentation at a conference
-
A phase I clinical trial on intratumoral (IT) administration of ipilimumab (IPI) plus nivolumab (NIVO) followed by intracavitary (IC) administration of nivolumab in patients with recurrent glioblastoma
Julia Katharina Schwarze (Speaker), Anne Vanbinst (Contributor)2020 → …Activity: Talk or presentation › Talk or presentation at a conference
-
Baseline total metabolic tumor volume assessed by 18FDG-PET/CT predicts outcome in advanced melanoma patients treated with pembrolizumab
Gil Awada (Speaker), Ibrahim Özdemir (Contributor), Julia Katharina Schwarze (Contributor), Emma Daeninck (Contributor), Odrade Gondry (Contributor), Yanina Jansen (Contributor), Teofila Seremet (Contributor), Marleen Keyaerts (Contributor), Hendrik Everaert (Contributor), Bart Neyns (Contributor)14 Dec 2018Activity: Talk or presentation › Talk or presentation at a conference